Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Trial Profile

A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Bb-21217 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors bluebird bio
  • Most Recent Events

    • 07 Jan 2019 According to a Celgene Corporation media release, data from the study is expected in 2019.
    • 04 Dec 2018 Results (n=8;data cut off June 15,2018) assessing safety, pharmacokinetics, efficacy and duration of effect of bb21217 presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 02 Dec 2018 Results presented in the bluebird bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top